Drug Trial Radar · NCT07749586
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
499
Planned (sponsor's estimate)
Start
Jul 29, 2026
Primary completion
Mar 31, 2031
Study completion Mar 31, 2032
Sponsor
- Lead sponsor
- Arvinas Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-6723. The investigational drug ARV-6723 will be given as an oral tablet on its own and also in combination with other drugs. Researchers think that ARV-6723 can help the body's immune system to better recognize, attack, and destroy cancer cells in adults with advanced solid tumors. ARV-6723 is an investigational drug, and this is the first time ARV-6723 will be used in humans. Depending on the treatment assignment, the investigational drug, ARV-6723, will be given as an oral tablet either on its own (monotherapy) or in combination with pembrolizumab, either through a vein (intravenously or IV) or through an injection beneath the skin (subcutaneously or SQ). This study will include multiple parts: In Part A1 (Phase 1a), different small groups of participants will receive lower to higher doses of ARV-6723 as monotherapy or in combination with standard-dose of pembrolizumab. In Part A2 (Phase 1b), two groups of participants with specific tumor indication(s) (TBD) will receive one of two doses selected based on information from Part A1. Details of Part B will be determined based on information generated from Part A.
Conditions
- Advanced Solid Tumor
Interventions
ARV-6723Drug
Oral daily dose of ARV-6723 at an assigned dose.
PembrolizumabDrug
IV infusion or SQ injection Q3W at an assigned dose.
SOCDrug
Investigator's choice of SOC drugs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A1: Number of Dose-Limiting Toxicities (DLTs) of ARV-6723Time frame: 21 days from first ARV-6723 administration
- Part A1: Number of Participants With Adverse Events (AEs)Time frame: From the first dose of ARV-6723 through at least 28 days after the last dose (up to approximately 4.7 years)
- Part A2: Number of Participants With AEsTime frame: From the first dose of ARV-6723 through at least 28 days after the last dose (up to approximately 4.7 years)
- Part A2: Overall Response Rate (ORR) by computed tomography/magnetic resonance imaging (CT/MRI) Using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) Criteria Per Investigator AssessmentTime frame: Approximately 24 months
- Part B: ORR by CT/MRI using RECIST v1.1 Criteria Per Investigator AssessmentTime frame: Approximately 24 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Boston, Massachusetts · Recruiting
Clinical Trial Site
New York, New York · Recruiting
Clinical Trial Site
Huntersville, North Carolina · Recruiting
Clinical Trial Site
San Antonio, Texas · Recruiting
Clinical Trial Site
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.